Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody

Abstract

The trans-membrane proteins of the B7 family programmed cell death ligand-1 (PD-L1) and programmed death-1 (PD-1) play important roles in inhibiting immune responses and enhancing self-tolerance via T-cell modulation. Several therapeutic antibodies are used to promote T-cell proliferation by preventing interactions between PD-1/PD-L1. Recombinant technology appears to be quite useful in the production of such potent antibodies. In this study, we constructed recombinant molecules by cloning variable regions of the PD-L1 molecule into pMH3 vectors and transferring them into mammalian cell lines for expression. G418 supplementation was used to screen the recombinant clones, which were then maintained on serum-free medium. The full-length antibody was isolated and purified from the medium supernatant at a concentration of 0.5-0.8 mg/ml. Antibody binding affinity was investigated using ELISA and immunofluorescence methods. The protein-protein interactions (PPI) were determined using a docking approach. The SWISS model was utilized for homology modeling, while ZDOCK, Chimera, and PyMOL were used to validate 3D models. The Ramachandran plots were constructed using the SWISS model, which revealed that high-quality structures had a value of more than 90%. Current technologies allow for the accurate determination of antigen-antibody interactions.

Effective control of postoperative recurrence of pregnancy-related gastric cancer using anti-PD-1 as a monotherapy: a case report

“…Currently, more antibodies targeting PD-L1 have also become commercially available (28,29). Novel pharmaceutics development like computational analysis of PD-L1 may be allowed for the accurate determination of antigen-antibody interactions, which could improve the efficiency of immunotherapy (30,31). However, the clinical practice of anti-PD-1 monotherapy only involves some special cancer species, and the efficacy is still controversial (32, 33).…”

Tissue‐type plasminogen activator (tPA) homozygous Tyr471His mutation associates with thromboembolic disease

“…The scoring function was used to perform rigid docking of the two proteins, and the docking yielded 100 conformations. We selected the protein binding model with the lowest docking energy score and used PyMOL 12.1 to display the 3D graphics of this model 44 …”

“…We selected the protein binding model with the lowest docking energy score and used PyMOL 12.1 to display the 3D graphics of this model. 44 …”